‘Low but stable’ pharma growth in 2014
The ratings agency Fitch has said in its 2014 outlook report for global branded pharmaceuticals that it forecasts "single-digit revenue growth for the global pharmaceutical industry although ratings will remain stable in 2014".
New products and strong growth in emerging markets will only partially offset patent expiries, European pricing policies and weak US employment, Fitch predicts, yet gives positive comment on the pharmaceutical industry's continued investment value.
"Fitch expects 2012-2013 product launches will support intermediate- to long-term growth. Despite the moderate headwinds pressuring profitability and cash flow, global pharmaceuticals will remain one of the highest-rated industries in Fitch's portfolio."
Fitch Ratings.
In terms of industry movement, the agency said there would be a focus on "target, bolt-on acquisitions" in 2014, alongside more collaborations over the development of individual therapeutics.
Related news:
Branded pharma revenues to rise 2%-3% in 2014, says Fitch (Pharma Times).
Reference links:
Fitch: Low growth but stable outlook for global pharmaceuticals in 2014 (Fitch ratings agency release via Reuters).
2014 outlook: global branded pharmaceuticals (Fitch Ratings report; requires subscription)
